What is Panacea Life Sciences Hldgs Inc's earnings per share (EPS)?

Panacea Life Sciences Hldgs Inc (PLSH) reported diluted earnings per share of $-0.48 for fiscal year 2023. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Panacea Life Sciences Hldgs Inc Financials

PLSH

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2024 Currency USD FYE December

This page shows Panacea Life Sciences Hldgs Inc (PLSH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 15/100

Based on FY2023 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Panacea Life Sciences Hldgs Inc has an operating margin of -232.5%, meaning the company retains $-233 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -288.3% the prior year.

Growth

Panacea Life Sciences Hldgs Inc's revenue surged 15.8% year-over-year to $2.4M, reflecting rapid business expansion. This strong growth earns a score of 60/100.

Liquidity

Panacea Life Sciences Hldgs Inc's current ratio of 0.24 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 0/100, which could limit financial flexibility.

Cash Flow

While Panacea Life Sciences Hldgs Inc generated -$1.5M in operating cash flow, capex of $65K consumed most of it, leaving -$1.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

3/9

Panacea Life Sciences Hldgs Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.19x

For every $1 of reported earnings, Panacea Life Sciences Hldgs Inc generates $0.19 in operating cash flow (-$1.5M OCF vs -$8.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-3.6x

Panacea Life Sciences Hldgs Inc earns $-3.6 in operating income for every $1 of interest expense (-$5.5M vs $1.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.4M

YoY+15.8%

Panacea Life Sciences Hldgs Inc generated $2.4M in revenue in fiscal year 2023. This represents an increase of 15.8% from the prior year.

EBITDA

-$3.8M

YoY+8.7%

Panacea Life Sciences Hldgs Inc's EBITDA was -$3.8M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.7% from the prior year.

Net Income

-$8.0M

YoY-67.6%

Panacea Life Sciences Hldgs Inc reported -$8.0M in net income in fiscal year 2023. This represents a decrease of 67.6% from the prior year.

EPS (Diluted)

$-0.48

Panacea Life Sciences Hldgs Inc earned $-0.48 per diluted share (EPS) in fiscal year 2023.

Cash & Balance Sheet

Free Cash Flow

-$1.6M

YoY+61.1%

Panacea Life Sciences Hldgs Inc generated -$1.6M in free cash flow in fiscal year 2023, representing cash available after capex. This represents an increase of 61.1% from the prior year.

Cash & Debt

$101K

YoY+410.4%

5Y CAGR-8.9%

Panacea Life Sciences Hldgs Inc held $101K in cash against $0 in long-term debt as of fiscal year 2023.

Dividends Per Share

N/A

Shares Outstanding

18M

YoY+25.4%

Panacea Life Sciences Hldgs Inc had 18M shares outstanding in fiscal year 2023. This represents an increase of 25.4% from the prior year.

Margins & Returns

Gross Margin

47.0%

YoY+20.8pp

Panacea Life Sciences Hldgs Inc's gross margin was 47.0% in fiscal year 2023, indicating the percentage of revenue retained after direct costs. This is up 20.8 percentage points from the prior year.

Operating Margin

-232.5%

YoY+55.7pp

Panacea Life Sciences Hldgs Inc's operating margin was -232.5% in fiscal year 2023, reflecting core business profitability. This is up 55.7 percentage points from the prior year.

Net Margin

-336.1%

YoY-103.9pp

Panacea Life Sciences Hldgs Inc's net profit margin was -336.1% in fiscal year 2023, showing the share of revenue converted to profit. This is down 103.9 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$65K

YoY-59.9%

Panacea Life Sciences Hldgs Inc invested $65K in capex in fiscal year 2023, funding long-term assets and infrastructure. This represents a decrease of 59.9% from the prior year.

PLSH Income Statement

Metric	FY23	FY21	FY20	FY19	FY18	FY17
Revenue	$2.4M+15.8%	$2.1M-77.2%	$9.0M+2508.7%	$346K	$0	$0
Cost of Revenue	$1.3M-16.9%	$1.5M-44.1%	$2.7M+32.9%	$2.0M	$0	N/A
Gross Profit	$1.1M+107.6%	$541K-72.9%	$2.0M+217.5%	-$1.7M	$0	N/A
R&D Expenses	N/A	N/A	$0-100.0%	$22K-92.6%	$300K-15.7%	$356K
SG&A Expenses	$1.5M-4.1%	$1.5M-45.9%	$2.8M-0.4%	$2.8M+47.1%	$1.9M+57.0%	$1.2M
Operating Income	-$5.5M+6.6%	-$5.9M-12.9%	-$5.3M+50.7%	-$10.7M-338.1%	-$2.4M+22.0%	-$3.1M
Interest Expense	$1.6M+40.8%	$1.1M-26.9%	$1.5M+215.5%	$479K+3.2%	$464K+577.4%	$69K
Income Tax	N/A	N/A	N/A	N/A	$0	$0
Net Income	-$8.0M-67.6%	-$4.8M+8.6%	-$5.2M+47.8%	-$10.0M-131.0%	-$4.3M-12.3%	-$3.9M
EPS (Diluted)	$-0.48	N/A	N/A	N/A	N/A	N/A

Metric	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22
Revenue	$1.1M+10.0%	$960K+176.1%	$348K-12.8%	$399K-41.1%	$677K-32.1%	$998K+172.4%	$366K-22.0%	$469K
Cost of Revenue	$390K-5.6%	$414K+105.5%	$201K+2.5%	$196K-56.6%	$452K+111.2%	$214K-32.9%	$319K-3.8%	$332K
Gross Profit	$666K+21.8%	$547K+273.0%	$147K-27.7%	$203K-10.1%	$226K+103.6%	$111K+134.1%	$47K-65.7%	$138K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$249K-68.0%	$777K+180.8%	$277K+90.6%	$145K-43.6%	$257K+54.5%	$167K-36.3%	$262K+27.8%	$205K
Operating Income	-$1.1M+40.2%	-$1.8M-25.0%	-$1.4M-31.7%	-$1.1M+16.7%	-$1.3M+6.2%	-$1.4M+0.9%	-$1.4M-12.0%	-$1.2M
Interest Expense	$430K+4.2%	$412K+3.9%	$397K+8.1%	$367K-3.5%	$380K+0.3%	$379K-36.6%	$598K+4.9%	$570K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.4M+34.5%	-$2.2M-2.7%	-$2.2M-15.4%	-$1.9M-4.1%	-$1.8M-5.1%	-$1.7M+36.7%	-$2.7M-37.3%	-$2.0M
EPS (Diluted)	$-0.09	N/A	$-0.13-18.2%	$-0.11+8.3%	$-0.12	N/A	$-0.18-38.5%	$-0.13

PLSH Balance Sheet

Metric	FY23	FY21	FY20	FY19	FY18	FY17
Total Assets	$18.0M-24.4%	$23.8M-24.2%	$31.4M+291.2%	$8.0M+56001.0%	$14K-91.7%	$173K
Current Assets	$4.7M-48.8%	$9.1M-21.0%	$11.5M+374.3%	$2.4M+16899.5%	$14K-91.7%	$173K
Cash & Equivalents	$101K+410.4%	$20K-76.6%	$84K+358.5%	$18K+839.0%	$2K-98.8%	$161K
Inventory	$4.0M-5.9%	$4.3M-49.3%	$8.4M+528.6%	$1.3M	$0	N/A
Accounts Receivable	$264K+8.0%	$244K+66.0%	$147K+164.3%	$56K	$0	N/A
Goodwill	$3.0M+37.7%	$2.2M0.0%	$2.2M	N/A	N/A	N/A
Total Liabilities	$26.3M+57.5%	$16.7M-32.3%	$24.7M+728.4%	-$3.9M-214.1%	$3.4M+44.0%	$2.4M
Current Liabilities	$19.4M+93.1%	$10.1M-44.9%	$18.3M+379.5%	$3.8M+14.1%	$3.3M+39.8%	$2.4M
Long-Term Debt	N/A	N/A	$336K+80.5%	$186K-68.6%	$592K+923.9%	$58K
Total Equity	-$8.3M-216.7%	$7.1M+5.9%	$6.7M-43.8%	$11.9M+448.7%	-$3.4M-54.6%	-$2.2M
Retained Earnings	-$33.9M-102.3%	-$16.8M-39.9%	-$12.0M+42.7%	-$20.9M-98.6%	-$10.5M-70.0%	-$6.2M

Metric	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22
Total Assets	$17.4M-3.2%	$18.0M-4.0%	$18.7M+4.9%	$17.9M-3.8%	$18.6M-4.8%	$19.5M-2.5%	$20.0M-9.0%	$22.0M
Current Assets	$4.6M-0.3%	$4.7M-20.7%	$5.9M+2.2%	$5.7M-3.3%	$5.9M-6.8%	$6.4M-1.6%	$6.5M-20.1%	$8.1M
Cash & Equivalents	$108K+6.7%	$101K+6650.6%	$1K-81.7%	$8K-88.8%	$73K+953.5%	$7K-81.1%	$37K+0.7%	$37K
Inventory	$4.1M+1.2%	$4.0M-14.5%	$4.7M+7.7%	$4.4M+6.4%	$4.1M-7.9%	$4.4M+0.8%	$4.4M-1.5%	$4.5M
Accounts Receivable	$271K+2.6%	$264K-14.5%	$309K+13.5%	$272K-1.0%	$275K+33.3%	$206K-7.1%	$222K+1.1%	$220K
Goodwill	$3.0M0.0%	$3.0M0.0%	$3.0M+37.7%	$2.2M0.0%	$2.2M0.0%	$2.2M0.0%	$2.2M0.0%	$2.2M
Total Liabilities	$27.0M+2.9%	$26.3M+5.9%	$24.8M+6.0%	$23.4M+4.8%	$22.4M+3.3%	$21.6M+5.9%	$20.4M+3.6%	$19.7M
Current Liabilities	$20.4M+4.9%	$19.4M+4.9%	$18.5M+8.7%	$17.0M+7.3%	$15.9M+5.4%	$15.1M+9.1%	$13.8M+5.7%	$13.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$9.6M-16.1%	-$8.3M-36.3%	-$6.1M-9.3%	-$5.6M-46.5%	-$3.8M-77.2%	-$2.1M-387.5%	-$440K-119.5%	$2.3M
Retained Earnings	-$35.4M-4.3%	-$33.9M-7.0%	-$31.7M-7.3%	-$29.6M-6.7%	-$27.7M-6.9%	-$25.9M-7.0%	-$24.2M-12.5%	-$21.5M

PLSH Cash Flow Statement

Metric	FY23	FY21	FY20	FY19	FY18	FY17
Operating Cash Flow	-$1.5M+61.1%	-$3.9M+48.7%	-$7.6M-33.1%	-$5.7M-1133.8%	-$466K+62.3%	-$1.2M
Capital Expenditures	$65K-59.9%	$163K-94.9%	$3.2M+491.3%	$541K	$0	N/A
Free Cash Flow	-$1.6M+61.1%	-$4.1M+62.3%	-$10.8M-72.5%	-$6.3M-1250.0%	-$466K	N/A
Investing Cash Flow	-$65K-112.5%	$523K+117.0%	-$3.1M-50.9%	-$2.0M	$0	$0
Financing Cash Flow	$1.7M-49.5%	$3.3M+45.3%	$2.3M-70.6%	$7.8M+2446.1%	$307K-10.1%	$341K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22
Operating Cash Flow	-$357K-22801.2%	$2K+100.2%	-$729K-50.8%	-$483K-54.0%	-$314K+40.0%	-$523K+26.5%	-$711K+2.5%	-$729K
Capital Expenditures	$5K	N/A	N/A	$9K-38.6%	$15K-84.6%	$99K-22.4%	$127K+1516.4%	$8K
Free Cash Flow	-$362K	N/A	N/A	-$493K-49.7%	-$329K+47.1%	-$622K+25.8%	-$838K-13.7%	-$737K
Investing Cash Flow	-$5K+72.1%	-$18K+21.6%	-$23K-144.4%	-$9K+38.6%	-$15K+84.6%	-$99K+22.4%	-$127K-427.0%	$39K
Financing Cash Flow	$369K+218.6%	$116K-84.5%	$745K+74.2%	$428K+8.2%	$395K-33.2%	$592K-29.4%	$839K+25.0%	$671K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PLSH Financial Ratios

Metric	FY23	FY21	FY20	FY19	FY18	FY17
Gross Margin	47.0%+20.8pp	26.3%+4.1pp	22.1%+514.1pp	-491.9%	N/A	N/A
Operating Margin	-232.5%+55.7pp	-288.3%-230.0pp	-58.3%+3029.2pp	-3087.5%	N/A	N/A
Net Margin	-336.1%-103.9pp	-232.2%-174.2pp	-58.0%+2840.3pp	-2898.3%	N/A	N/A
Return on Equity	N/A	-67.3%+10.7pp	-78.0%+5.9pp	-83.9%	N/A	N/A
Return on Assets	-44.6%-24.5pp	-20.1%-3.4pp	-16.7%+108.3pp	-125.0%+30227.2pp	-30352.1%-28116.3pp	-2235.8%
Current Ratio	0.24-0.7	0.90+0.3	0.630.0	0.64+0.6	0.00-0.1	0.07
Debt-to-Equity	-3.17-5.5	2.35+2.3	0.05+0.0	0.02+0.2	-0.17-0.1	-0.03
FCF Margin	-66.7%+131.7pp	-198.3%-78.1pp	-120.3%+1698.6pp	-1818.9%	N/A	N/A

Metric	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22
Gross Margin	63.1%+6.1pp	56.9%+14.8pp	42.1%-8.7pp	50.8%+17.5pp	33.3%+22.2pp	11.1%-1.8pp	12.9%-16.5pp	29.4%
Operating Margin	-100.1%+84.0pp	-184.1%+222.4pp	-406.5%-137.4pp	-269.1%-78.7pp	-190.4%-52.5pp	-137.9%+241.3pp	-379.2%-115.0pp	-264.1%
Net Margin	-136.9%+93.1pp	-230.0%+388.4pp	-618.4%-151.3pp	-467.1%-202.7pp	-264.4%-93.6pp	-170.8%+564.7pp	-735.6%-317.7pp	-417.9%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-87.0%
Return on Assets	-8.3%+4.0pp	-12.3%-0.8pp	-11.5%-1.0pp	-10.4%-0.8pp	-9.7%-0.9pp	-8.8%+4.7pp	-13.5%-4.5pp	-8.9%
Current Ratio	0.23-0.0	0.24-0.1	0.32-0.0	0.34-0.0	0.37-0.0	0.42-0.0	0.47-0.2	0.62
Debt-to-Equity	-2.81+0.4	-3.17+0.9	-4.08+0.1	-4.21+1.7	-5.88+4.2	-10.09+36.3	-46.43-55.2	8.75
FCF Margin	-34.3%	N/A	N/A	-123.4%-74.9pp	-48.6%+13.7pp	-62.3%+166.6pp	-228.9%-71.9pp	-157.1%

Note: Shareholder equity is negative (-$8.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.24), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

WEST IS BRANDS INC WIBFF

$1.5M

Cbd Life Science CBDL

$593K

Ovation OVATF

$814K

Hemp HEMP

$1.2M

Can B Corp CANB

$1.4M

Frequently Asked Questions

What is Panacea Life Sciences Hldgs Inc's annual revenue?

Panacea Life Sciences Hldgs Inc (PLSH) reported $2.4M in total revenue for fiscal year 2023. This represents a 15.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Panacea Life Sciences Hldgs Inc's revenue growing?

Panacea Life Sciences Hldgs Inc (PLSH) revenue grew by 15.8% year-over-year, from $2.1M to $2.4M in fiscal year 2023.

Is Panacea Life Sciences Hldgs Inc profitable?

No, Panacea Life Sciences Hldgs Inc (PLSH) reported a net income of -$8.0M in fiscal year 2023, with a net profit margin of -336.1%.

What is Panacea Life Sciences Hldgs Inc's EBITDA?

Panacea Life Sciences Hldgs Inc (PLSH) had EBITDA of -$3.8M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.

What is Panacea Life Sciences Hldgs Inc's gross margin?

Panacea Life Sciences Hldgs Inc (PLSH) had a gross margin of 47.0% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.

What is Panacea Life Sciences Hldgs Inc's operating margin?

Panacea Life Sciences Hldgs Inc (PLSH) had an operating margin of -232.5% in fiscal year 2023, reflecting the profitability of core business operations before interest and taxes.

What is Panacea Life Sciences Hldgs Inc's net profit margin?

Panacea Life Sciences Hldgs Inc (PLSH) had a net profit margin of -336.1% in fiscal year 2023, representing the share of revenue converted into profit after all expenses.

What is Panacea Life Sciences Hldgs Inc's free cash flow?

Panacea Life Sciences Hldgs Inc (PLSH) generated -$1.6M in free cash flow during fiscal year 2023. This represents a 61.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Panacea Life Sciences Hldgs Inc's operating cash flow?

Panacea Life Sciences Hldgs Inc (PLSH) generated -$1.5M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.

What are Panacea Life Sciences Hldgs Inc's total assets?

Panacea Life Sciences Hldgs Inc (PLSH) had $18.0M in total assets as of fiscal year 2023, including both current and long-term assets.

What are Panacea Life Sciences Hldgs Inc's capital expenditures?

Panacea Life Sciences Hldgs Inc (PLSH) invested $65K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.

How many shares does Panacea Life Sciences Hldgs Inc have outstanding?

Panacea Life Sciences Hldgs Inc (PLSH) had 18M shares outstanding as of fiscal year 2023.

What is Panacea Life Sciences Hldgs Inc's current ratio?

Panacea Life Sciences Hldgs Inc (PLSH) had a current ratio of 0.24 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.

What is Panacea Life Sciences Hldgs Inc's debt-to-equity ratio?

Panacea Life Sciences Hldgs Inc (PLSH) had a debt-to-equity ratio of -3.17 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Panacea Life Sciences Hldgs Inc's return on assets (ROA)?

Panacea Life Sciences Hldgs Inc (PLSH) had a return on assets of -44.6% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.

What is Panacea Life Sciences Hldgs Inc's cash runway?

Based on fiscal year 2023 data, Panacea Life Sciences Hldgs Inc (PLSH) had $101K in cash against an annual operating cash burn of $1.5M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Panacea Life Sciences Hldgs Inc's debt-to-equity ratio negative or unusual?

Panacea Life Sciences Hldgs Inc (PLSH) has negative shareholder equity of -$8.3M as of fiscal year 2023, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Panacea Life Sciences Hldgs Inc's Piotroski F-Score?

Panacea Life Sciences Hldgs Inc (PLSH) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Panacea Life Sciences Hldgs Inc's earnings high quality?

Panacea Life Sciences Hldgs Inc (PLSH) has an earnings quality ratio of 0.19x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Panacea Life Sciences Hldgs Inc cover its interest payments?

Panacea Life Sciences Hldgs Inc (PLSH) has an interest coverage ratio of -3.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Panacea Life Sciences Hldgs Inc?

Panacea Life Sciences Hldgs Inc (PLSH) scores 15 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.